Sign in
Taking people in United StatesPhase 1

Sound-wave device with diclofenac patch compared with diclofenac patch alone for osteoarthritis pain

Compares a sound-wave treatment with a pain-relief patch in people with osteoarthritis.

Key facts

Who runs it
ZetrOZ, Inc.
Where
Tampa, United StatesSee the site
Trial code
Registry title
Sustained Acoustic Medicine for Osteoarthritis Pain
Status
Recruiting
Phase
Phase 1
People taking part
200 people, planned
Started
14 Feb 2022
Planned end
31 May 2026
Type of study
Interventional
Treatments tested
  • Sustained Acoustic Device with 2.5% Diclofenac Patch
  • 2.5% Diclofenac Patches
Record updated
27 February 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild to moderate osteoarthritis (joint wear) pain in the knee, shoulder, elbow, ankle, hip or spine. It tests a wearable ultrasound device used with a diclofenac pain patch.

Age
35 to 85 years
Sex
All sexes
Disease stage
Mild to moderate osteoarthritis diagnosed by a doctor (OARSI atlas grades 1-2). Frequent pain score between 3-7 out of 10 in the week before joining. Pain must lower quality of life.
Earlier treatment
People must not use or start opioid or non-opioid pain medicines. They must stop other treatments on the area, such as nerve stimulation or ultrasound, and use no other creams or gels.

Main reasons for not taking part

  • Pregnancy, a pacemaker, or needing oxygen support
  • Joint replacement or other surgery in the affected area in the past 6 months
  • Cancer, infection, open sores or loss of feeling in the treatment area, or known nerve disease
  • Allergy to aspirin or other NSAIDs, or an inherited tendency to bleed heavily
  • Arthritis caused by a metabolic or inflammatory disease

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Have physician-diagnosed mild to moderate knee, shoulder, elbow, ankle, hip, or spine osteoarthritis OA (OARSI atlas grades 1-2) or also referred to as Degenerative Joint Disease (DJD)
  • Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA
  • Are between 35-85 years of age
  • Report a frequent pain score between 3-7 (range: 0-10) during the week preceding enrollment
  • Report that knee, shoulder, elbow, ankle, hip, or spine pain negatively affects quality of life
  • Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved treatment provided to the subject at the initiation of the study
  • Are deemed appropriate by their physician or by the study site physician to participate
  • Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device
  • Not use or initiate opioid and/or non-opioid analgesic medications
  • Be willing to discontinue any other interventional treatment modalities on the treatment area during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound)

Who cannot take part

  • Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening
  • Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia
  • Have knee, shoulder, elbow, ankle, or hip replacement or other surgical intervention, in the affected area in the past 6 months
  • Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions
  • Has a malignancy in the treatment area
  • Has an active infection, open sores, or wounds in the treatment area
  • Has a known neuropathy (disease of the brain or spinal nerves)
  • Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage)
  • Has an allergy to aspirin or other NSAIDs
  • Cannot successfully demonstrate the ability to put on and take off the device
  • Is pregnant
  • Is a prisoner
  • Has a pacemaker
  • Requires oxygen support
  • Have a secondary cause of arthritis (metabolic or inflammatory)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 35 and 85 years old?

Where in United States

  • James A. Haley Veterans HospitalTampa, United StatesContact: Samuel Phillips, Ph.D.Taking people

About the trial

What the trial wants to find out

The purpose of this study is to compare Sustained Acoustic Medicine treatment to topical pain relief gel for the symptomatic management of osteoarthritis. The study will measure pain and function scores for patients undergoing treatment.

The group in the trial

  • SAM Ultrasound Device and Diclofenac PatchTreatment being tested

    Patients receive treatment from the wired SAM Ultrasonic Diathermy Device for 4 hours at least 5 days a week for 8 weeks combined with 2.5% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

    Treatment: Sustained Acoustic Device with 2.5% Diclofenac Patch and 2.5% Diclofenac Patches

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Sustained Acoustic Medicine for Osteoarthritis Pain
Plain-language title
Sound-wave device with diclofenac patch compared with diclofenac patch alone for osteoarthritis painGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05254574, who can take part
Record updated
27 February 2025